Abstract
BackgroundResistance to an immune checkpoint inhibitor (ICI) is a major obstacle in cancer immunotherapy. The causes of ICI resistance include major histocompatibility complex (MHC)/histocompatibility locus antigen (HLA) class I loss,...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have